Narayana Hrudayalaya
- Market cap
- ₹ 34,001 Cr.
- P/E
- 40.9x
- P/B
- 7.58x
- 52-week range
- 1,589 – 2,093.3
- ROE
- 21%
- ROCE
- 16%
- Dividend yield
- 0.3%
- Debt / equity
- 1.29
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE, BSE
About
Narayana Hrudayalaya Limited is engaged in medical and healthcare services. The Company operates a network of multispecialty and super-specialty hospitals across multiple locations. Its operating segment is Medical and Healthcare Related Services. Its medical services include anesthesiology, audiology, breast oncology and oncoplastic surgery, clinical psychology, congenital adult heart disease, cardiac sciences, developmental and behavioral pediatrics, endocrinology and diabetology, gastrointestinal oncology, gynecologic oncology, hepatology and liver transplantation, interventional and endovascular radiology, medical gastroenterology, neuro rehabilitation, pediatric hematology oncology, speech and swallow rehabilitation, thoracic and vascular surgery, vascular and endovascular surgery, surgical gastroenterology, and surgical oncology, among others. It has a network of over 18 hospitals and three heart centers across India, along with an international presence in the Cayman Islands.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →Narayana Hrudayalaya against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)40.9 against a typical 48.9: cheaper than most peers (1st = cheapest).16th of 40
- Sales growth+78.1% against a typical +21.1% from a year earlier.6th of 34
- Profit growth+5.1% against a typical +13% from a year earlier.19th of 31
- Share price, 3 months−16.9% against a typical −10.9%.22nd of 34
- Size₹ 34,001.2 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).6th of 36
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]AA | Stable | 19 Jan 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 19 Jan 2026 | Reaffirmed | [ICRA]AA /[ICRA]A1+ → [ICRA]AA | — | ICRA | ₹ 5,335 Cr. | |
| 10 Nov 2025 | Rating action | [ICRA]AA /[ICRA]A1+ | — | ICRA | ₹ 5,285 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 30 Oct 2026Upcoming | Financial Results | To consider and approve the un-audited standalone and consolidated financial results of the Company for the quarter and half year ended September 30, 2026 |
| 31 Jul 2026 | Financial Results | To consider and approve the un-audited standalone and consolidated financial results of the Company for the quarter ended June 30, 2026 |
| 22 May 2026 | Financial Results/Dividend/Fund Raising/Other business matters | To consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, dividend, Fund Raising and other business matters |
| 13 Feb 2026 | Financial Results | To consider and approve the un-audited Standalone and ConsolidatedFinancial Results of the Company for the quarter ended December 31, 2025 |
| 14 Nov 2025 | Financial Results | To consider and approve un-audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2025 |
| 1 Aug 2025 | Financial Results/Fund Raising | To consider and approve the financial results for the period ended Jun 30, 2025 and Fund Raising |
| 23 May 2025 | Financial Results/Dividend/Fund Raising | NARAYANA HRUDAYALAYA LTD. has informed the Exchange about Board Meeting to be held on 23-May-2025 to consider and approve the audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2025 and dividend/Fund Raising |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,305 | 1,204 | 1,246 | 1,306 | 1,367 | 1,335 | 1,475 | 1,507 | 1,644 | 2,151 | 2,594 | 2,684 |
| Expenses | 997 | 925 | 955 | 1,004 | 1,058 | 1,027 | 1,118 | 1,171 | 1,243 | 1,786 | 2,086 | 2,216 |
| Operating Profit | 308 | 279 | 291 | 302 | 309 | 307 | 358 | 337 | 401 | 365 | 508 | 468 |
| OPM % | 24% | 23% | 23% | 23% | 23% | 23% | 24% | 22% | 24% | 17% | 20% | 17% |
| Other Income | 18 | 18 | 26 | 24 | 23 | 18 | 20 | 24 | 24 | −29 | 25 | 35 |
| Interest | 23 | 25 | 28 | 34 | 35 | 37 | 41 | 45 | 42 | 65 | 91 | 87 |
| Depreciation | 55 | 63 | 65 | 61 | 65 | 70 | 82 | 84 | 87 | 122 | 154 | 156 |
| Profit before tax | 248 | 209 | 225 | 231 | 232 | 219 | 254 | 232 | 296 | 149 | 288 | 260 |
| Tax % | 9% | 10% | 15% | 13% | 14% | 12% | 22% | 15% | 13% | 15% | 22% | 20% |
| Net Profit | 227 | 188 | 191 | 202 | 199 | 193 | 197 | 197 | 258 | 127 | 224 | 207 |
| EPS in Rs | 11.09 | 9.2 | 9.33 | 9.85 | 9.72 | 9.44 | 9.65 | 9.62 | 12.64 | 6.2 | 10.96 | 10.14 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 17%
- 5 Years
- 25%
- 3 Years
- 20%
- TTM
- 60%
- 10 Years
- 42%
- 5 Years
- 155%
- 3 Years
- 12%
- TTM
- 9%
- 10 Years
- 19%
- 5 Years
- 29%
- 3 Years
- 22%
- TTM
- —
- 10 Years
- 20%
- 5 Years
- 26%
- 3 Years
- 25%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Narayana Hrudayalaya | ₹ 1,720.00 | ₹ 34,001 Cr. | 40.9x | 7.6x | 21% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Global Health | ₹ 1,165.00 | ₹ 31,449 Cr. | 63.7x | 8.9x | 15.2% | 12.6% |
Management
- Devi Prasad Shetty
- Executive Chairman of the Board, Whole Time Director
- Emmanuel Rupert
- Group Chief Executive Officer, Managing Director, Executive Director
- Viren Prasad Shetty
- Executive Vice Chairman of the Board
- Sandhya Jayaraman
- Group Chief Financial Officer
- Sridhar Seshiah
- Group Company Secretary, Legal and Compliance Officer
Prices are delayed and for information only. Nothing on this page is investment advice.